大脑脂质结合蛋白在肌缩性侧面硬化症的发病过程中的潜在影响
Qi Zhou1, Qing Kang2, Wenzhi Chen2
1Department of Neurology, The First People's Hospital of Fuzhou City, Fuzhou, China.
Science progress
|July 13, 2023
概括
脑脂结合蛋白 (BLBP) 表达在小鼠的肌缩侧面硬化症 (ALS) 进展期间在脊髓中增加. 这表明BLBP可能通过影响神经前体细胞在ALS的发病过程中发挥作用.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 病理学 病理学 病理学
背景情况:
- 肌缩侧面硬化症 (ALS) 的发病因子尚未完全理解.
- 脑脂结合蛋白 (BLBP) 的异常变化与ALS有关.
- 需要进一步的研究来阐明BLBP在ALS中的特定作用.
研究的目的:
- 调查BLBP在ALS病变发生中的潜在作用.
- 分析不同脊髓区域和ALS进展阶段的BLBP表达模式.
- 确定BLBP在ALS中的细胞局部化和潜在功能.
主要方法:
- 使用的Tg(SOD1*G93A) 1Gur (TG) 小鼠和年龄匹配的野生类型 (WT) littermates.
- 检查了BLBP表达在前发病,发病和进展阶段.
- 采用光免疫组织化学和西部涂抹进行分析.
主要成果:
- 在各种脊髓解剖区域发现了BLBP阳性细胞,特别是在前后角.
- 在WT和TG小鼠中,BLBP的表达随着疾病进展而增加,TG小鼠从发病到进展的时间显著增加.
- 在神经元,星体细胞,放射性质细胞和神经前体细胞 (NPC) 中检测到BLBP,在TG小鼠中,增加的BLBP与神经细胞减少相关.
结论:
- 在脊髓中BLBP的分布和增加表达表明它与ALS的发展有关.
- 通过调节神经前体细胞 (NPCs),BLBP可能会影响ALS的发病过程.
- 作为潜在的治疗标或ALS的生物标志物,BLBP需要进一步调查.
相关概念视频
00:49The Blood-brain Barrier
47.6K
Overview
47.6K
03:03Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K
01:15Parkinson's Disease: Overview
604
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
604
01:26Alzheimer's Disease: Overview
525
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
525
01:26Cross-bridge Cycle
117.7K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
117.7K
01:22Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K